An interventional study of Eustachian tube dilation added to standard treatment and Standard treatment in Otitis Media, Eustachian Tube Disorder and Chronic Otitis Infections in pédiatric Patients, sponsored by University Hospital, Montpellier. Not yet recruiting at 7 sites in France. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical investigation is to evaluate the effectiveness of ETD + standard treatment versus standard treatment only, on the improvement of the tympanic membrane retraction, up to 18 months after intervention in children aged ]8-17[ with posterior mesotympanic retraction and middle ear effusion.
244 studies on the registry are indexed under Otitis Media; 32 are open to participants now.
This study's planned enrollment of 272 is above the median of 165 across 174 interventional studies indexed under Otitis Media.
Browse Otitis Media studies →University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present. ETD involves using a transnasal balloon catheter, during general anesthesia, by the surgeon in charge of the patient. The device will be an Acclarent Aera 6x16 mm balloon, with a pressure set at 12 atm for 2 minutes in the eustachian tube. The manufacturer of the ETD device will organize a training session with hands-on on simulator, for all the principal investigators prior to the start of the study, to ensure homogenous intervention.
Device: Eustachian tube dilation added to standard treatment
Standard treatment involves the placement of a tympanostomy tube and adenoidectomy if a hypertrophy of the adenoids is present, during general anesthesia, by the surgeon in charge of the patient. Tube placement will be in the anterior or inferior part of the tympanic membrane. Different design and brand of tympanostomy tube exist and are used in the different centers, leading to putative slightly different outcomes in term of adverse events related to the tympanostomy tube and duration. To decrease the cohort's heterogeneity, we propose to utilize the same tympanostomy tube for all the patients included in the study (Shepard's tympanostomy tube).
Device: Standard treatment
Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical, coupled with the Acclarent Aera™ Eustachian Tube Balloon Dilation System.
Medical device: Shepard tympanostomy tube, reference PRO 000 310P, manufactured by Pouret Medical.
Tympanic membrane retraction
The assessment of tympanic membrane retraction is treated as a survival variable. Tympanic membrane retraction will be blindly assessed by an adjudication committee, through recorded otoendoscopy, based on the Sade's classification (in grade 0, I, II, III, IV, or V). The delay will be calculated as the time from intervention to improvement in tympanic membrane retraction (event), to loss of follow up (censoring), or to the study endpoint (censoring).
Time frame: Tympanic membrane retraction will be assessed 3 times during the follow up: at 6, 12 and 18 months.
Mesotympanic retractation
Mesotympanic retractation according to Sade's classification
Time frame: 6, 12 and 18 months
Audiometry thresholds
Mean of the air-bone gap at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz
Time frame: 6, 12 and 18 months
Tympanometry profile
Tympanometry profile (A, B or C)
Time frame: 6, 12 and 18 months
The quality of life
Quality of Life measured through the OM-6 questionnaires
Time frame: 6, 12 and 18 months
The quality of life
Quality of Life measured through the PedsQL™ 4.0 questionnaires
Time frame: 6, 12 and 18 months
Adverse events in both arms
Occurrence of adverse events and serious events during the first week, coded according to MedDRA.
Time frame: during the first week
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Jun 2030, 39 months later.
Of 36 non-industry interventional studies with no phase under Otitis Media, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's planned 39 months is close to that.
Counting every sponsor, half of 45 studies reached it within 38 months; a quarter within 13 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →